Video:
FDA Recall of Insulet Omnipod 5 Pods Raises Safety Concerns Over Connected Insulin Delivery Devices

A recall posted by the U.S. Food and Drug Administration (FDA), 2026 window has brought renewed scrutiny to connected drug delivery systems. The action involves specific Omnipod 5 insulin pump pods manufactured by Insulet Corporation, a widely used wearable insulin delivery platform in the United States. The FDA’s notice outlines potential malfunctions that could interrupt insulin delivery, creating serious risks for patients and raising broader concerns for healthcare providers managing technology-dependent care.

While insulin pumps are typically associated with outpatient diabetes management, this recall highlights how connected medical devices are increasingly intersecting with hospital and surgical workflows, especially as more procedures shift to ambulatory settings where patients arrive with pre-existing wearable systems in use.

The FDA recall identifies certain Omnipod 5 Pods that may fail to deliver insulin as intended. These pods are part of an automated insulin delivery system that integrates with continuous glucose monitoring (CGM) technology to adjust insulin dosing in real time.

According to the FDA, the issue involves unexpected interruptions in insulin delivery or inaccurate dosing, which may occur without sufficient warning to the user. This creates a risk of both hyperglycemia (high blood sugar) and hypoglycemia (low blood sugar), depending on the nature of the malfunction.

Insulet initiated the recall after identifying the issue and has advised patients and providers to stop using affected pods and transition to alternative insulin delivery methods. The FDA has published detailed instructions for identifying impacted lot numbers and managing affected devices.

This recall is part of a broader series of medical device safety alerts and recalls issued in late April and early May, reflecting increased regulatory vigilance around device performance and patient safety.

The implications of this recall extend beyond diabetes care. In modern surgical environments, particularly in outpatient and minimally invasive settings, patients often arrive with active wearable medical devices, including insulin pumps.

This introduces new variables into surgical planning:

• Preoperative evaluation must include device verification: Surgical teams must confirm that patient-owned devices are functioning properly and are not subject to recall.

• Backup supply planning becomes essential: Facilities may need to maintain additional insulin delivery options, such as syringes or IV insulin kits, to manage patients whose devices are compromised.

• Workflow disruptions: Device failures can delay procedures or require additional monitoring resources, particularly in pre-op and recovery units.

“According to the FDA, interruptions in insulin delivery can rapidly lead to serious adverse events, particularly in insulin-dependent patients,” reinforcing the need for real-time device oversight in clinical settings.

For supply chain leaders, this expands the scope of responsibility to include patient-dependent technologies that can directly impact care delivery.

The recall affects multiple stakeholders:

• Patients using Omnipod 5 systems must identify whether their pods are included in the recall and switch to alternative methods if necessary.

• Hospitals and ASCs must integrate device checks into intake and preoperative protocols.

• Clinicians, including surgeons and anesthesiologists, must adjust care plans for patients relying on affected devices.

• Procurement teams may need to increase stock of traditional insulin delivery supplies to ensure continuity of care.

Ambulatory surgery centers are particularly vulnerable due to their reliance on efficient, streamlined workflows and limited inventory buffers.

This event reflects a broader trend in healthcare: the rapid adoption of automated, software-driven medical devices. Systems like Omnipod 5 offer improved convenience and outcomes but also introduce new risks related to software, connectivity, and system integration.

“According to reporting from MassDevice, the rise of connected medical technologies is increasing the complexity of device monitoring and recall management across healthcare systems.”

For the surgical supply chain, this means:

• Expanding recall tracking systems to include patient-owned devices

• Increasing coordination between clinical, IT, and procurement teams

• Evaluating vendors not only on performance but also on reliability and recall history

As hospitals continue to adopt integrated care models, the ability to manage these risks will become a key differentiator in operational performance.

“According to the FDA’s safety communication, healthcare providers should ensure that patients using affected Omnipod 5 Pods are transitioned to alternative insulin delivery methods without delay to prevent adverse events.”

Industry experts emphasize that device reliability is now a system-wide concern, requiring collaboration across departments. As more care becomes technology-enabled, the margin for undetected failure decreases, making proactive monitoring and rapid response essential.

Healthcare providers and supply chain leaders should take immediate steps:

• Review the FDA recall notice in full to identify affected products

• Screen patients for wearable device usage during intake and preoperative evaluation

• Ensure availability of backup insulin delivery supplies

• Coordinate with endocrinology teams for safe patient transitions

• Strengthen recall response protocols to include connected and patient-owned devices

To access the full FDA recall notice and official guidance, use the direct source below.